Pharmahungary Group

MedGenome is a genomics-driven research and diagnostics company with a mission to improve global health by decoding the genetic information contained in an individual’s genome. Our powerful genomics solutions accelerate biomarker identification and discovery research for pharma and biotech companies. Our unique access to genomics data with clinical and phenotypic data provides insights into complex diseases at the genetic and molecular level to facilitate research in personalized healthcare.

MedGenome Inc. has its Corporate Headquarters and a Next Generation Sequencing (NGS) lab in Foster City, California, US.

MedGenome Inc. offers Next-Generation Sequencing based genomic solutions in cancer immunotherapy and metabolic diseases. Its unique access to genomics data with clinical and phenotypic data provides insights into complex diseases at the genetic and molecular level, to facilitate research in personalized health care.
MedGenome Labs is the market leader for genetic diagnostic testing in India and South Asia, applying Next Generation Sequencing (NGS) techniques to large disease cohorts in cancer, eye and neurological disorders, diabetes, cardiovascular diseases and rare cancers.

Our NGS lab in Bangalore is the highest throughput lab in South-East Asia. We offer more than 400 genetic tests across different disease areas such as Oncology, Neurology, Cardiology, Ophthalmology and Rare diseases. MedGenome is the only NGS facility in the country to be validated and verified to run the highly accurate and comprehensive non-invasive prenatal test (Panorama). MedGenome has two state-of-the-art sequencing labs – A 10,000 sq. ft. in Bangalore and 5000 sq. ft. lab in Cochin – the only company in India to do so.

MedGenome has recently purchased the Illumina NovaSeq platform to fuel its genomic research services capability. Our dedicated team of biologists, bioinformaticians and statisticians analyze omics data to enable research projects by global pharma and biotech.

Founded in 2002, CELPROGEN is a biotechnology company, with over 5000 products in the market, focused on developing stem cell research and therapeutics products for regenerative medicine in cardiology, oncology, diabetes & neurology. All of Celprogen’s biological products, including stem cells, cancer stem cells, iPC’s & media with specific ECM’s, are manufactured and produced in the United States of America.

CELPROGEN provides novel molecular diagnostics and therapeutic product development solutions for Biotechnology, Pharmaceutical, In-vitro diagnostics and academic partnership for drug discovery.

It has 3 divisions:

• Therapeutic Division: Focused on Drug Discovery efforts to develop Pharmaceutical agents and Drugs in the following categories: Cardiovascular, Diabetes, Neurological, Oncology,Renal and Metabolic disorders.
• Life Science Division: Provides research tools & solutions for assays, enzymes, antibodies, antigens, stem cells, Tissue culture expansion and differentiation media, primary and established cell cultures, tumor markers, cardiac markers, proteomic and genomic reagents and assay systems for life science academic and pharmaceutical communities.
• Device Division: Provides novel ELISA based assay, protein array, DNA array and cellular based assay systems that are cost effective for Research and In-vitro diagnostics Industries.

Cureline, Inc., is a global translational and biomarker CRO, focused on providing biospecimens procurement, management, and analysis services in the following areas: molecular diagnostics, biomarkers, drug R&D, preventive and predictive medicine, translational research, and personalized medicine. Since 2003, we have collaborated with leading clinical and research centers in the USA, Europe, and Asia on human tissue acquisition, processing and distribution.

We have expertise in a wide range of therapeutic fields, including Oncology, Inflammation, Cardiovascular diseases, Diabetes/Obesity, Infectious diseases (including in-hospital infections), CNS disorders, Inherited conditions, and others.

Cureline provides high-quality, well characterized human biospecimens and tissue-related services to biomedical research community allowing accelerated identification and validation of drug targets, development of companion diagnostic tests, discovery and development of biomarker assays and, overall, facilitating the personalized approach in medicine.

Our offices are located in South San Francisco (California, USA), St. Petersburg (Russia) and in Central/South-Pacific Asia. 25 employees with advanced degrees in life sciences, medicine and business development ensure implementation of the complex projects.

Kinexus Bioinformatics Corporation maps and monitors the molecular communications networks of living cells for biomedical research into the diagnosis, prognosis and treatment of human diseases. In particular, the company tracks enzymes called protein kinases that control other proteins by carrying out their phosphorylation at regulatory sites known as phosphosites. Phosphosites act as on/off switches for proteins. Their malfunction has been linked to more than 400 human diseases, including cancer, cardiovascular disease, diabetes and inflammation.

Currently, Kinexus measures the presence and activation states of over 650 different protein kinases and other regulatory proteins and many of their phosphosites in cell and tissue specimens through our integrated platform of cell culture, protein microarray, immunoblotting, mass spectrometry and immunohistochemistry services.

These innovative proprietary services utilize unique and stringent screening methods to facilitate the discovery and validation of biomarkers, drug targets and the rapid exclusion of inappropriate drug leads in the early stages of the drug discovery process. This is further augmented by a suite of open source, online bioinformatics services that are offered by Kinexus. Our bioinformatics studies are helping us to create new tools for biomedical research that include enzymes, antibodies and peptides.

For over 12 years, Kinexus has provided our unique services to over 1600 laboratories in 35 countries.

AKRN Scientific Consulting is a clinical research and regulatory consulting firm for medical devices and IVD.

AKRN is based in Spain and Sweden.

We provide clinical development services on a stand-alone basis, or as part of an integrated full-service solution together with our European CRO-partners.

Our clients include MedTech start-up companies as well as multi-national companies.

We are committed to partner with Medical Device companies developing innovative technologies improving health care for more people.

We are highly qualified, experienced, and accountable clinical research professionals that guarantee cost-effective and successful solutions crafted to each client’s needs. We combine therapeutic expertise and decades of industry know-how with excellent service and responsiveness to support our customers with solutions that can stand up to rigorous scientific and regulatory evaluations.

We follow the national and international current standards (ICH/GCP guidelines, European regulations, and national and regional legislation), and the client or AKRN internal SOPs.

Services:
-Clinical Trial Services
-Clinical Strategy and Planning
-Study Design
-Clinical Monitoring
-Post Market Clinical Follow Up PMCF

Regulatory Services:
-CE Mark Strategic Planning
-Technical File | Design Dossier
-EU MDD to MDR Transition
-EU IVDD to IVDR Transition
-Clinical Evaluation Report CER

Key Medical Areas:

In-Vitro Diagnostic IVD

Cardiovascular
-Heart Valve Disease
-Aortic Disease
-Atrial Fibrillation
-Coronary Artery Disease
-Hypertension
-Endovascular Aortic Repair EVAR
-Percutaneous Coronary Interventions PCI
-Transcatheter Aortic Valve Implantation TAVI

Neurovascular
-Neuromodulation
-Spinal Cord Injuries
-Neurovascular Mechanical Thrombectomy

General
-Critical Care and Sepsis Management
-Minimal Invasive Surgery

Software
-AI | Machine Learning
-MDSW | SaMD

Odontology
-Implant and Digital Dentistry

Endocrinology
-Endocrinology and Diabetes